The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.
cardiovascular disease
cohort study
diabetic
nephropathy
type 1 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
revised:
03
10
2024
received:
01
07
2024
accepted:
07
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Vitamin K deficiency is common in persons with kidney disease, which is a known complication of diabetes. We aimed to assess the association of vitamin K status as reflected by plasma dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) with mortality, cardiovascular disease (CVD) and progression to end-stage kidney disease (ESKD) in persons with type 1 diabetes. We analysed plasma dp-ucMGP in stored baseline samples from a cohort of 667 persons with type 1 diabetes (baseline visit: 2009-2011). Information on mortality and CVD was obtained through linkage to registers. Cox-proportional hazards models were applied to estimate hazard ratios (HRs) of mortality, CVD and ESKD per one doubling of dp-ucMGP. A total of 53 deaths were recorded during follow-up. Persons with higher dp-ucMGP (reflecting lower vitamin K status) had higher mortality in the unadjusted model (HR: 2.06 [95% confidence interval-CI: 1.22-3.45]), but not in the fully adjusted model (HR: 0.88 [95% CI: 0.44-1.73]). Particularly, adjustment for glomerular filtration rate and urinary albumin excretion rate attenuated the HR. A similar pattern was observed in unadjusted models for incidence of CVD (HR: 1.58 [95% CI: 1.03-2.42]) and risk of ESKD (HR: 7.62 [95% CI: 4.25-13.68]). In the fully adjusted models, the HRs became statistically insignificant. In persons with type 1 diabetes, lower vitamin K status was associated with higher mortality, CVD and progression to ESKD, however, not after adjustment for other risk factors. Interventional studies are needed to elucidate the role of vitamin K in persons with type 1 diabetes.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Vitamin K deficiency is common in persons with kidney disease, which is a known complication of diabetes. We aimed to assess the association of vitamin K status as reflected by plasma dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) with mortality, cardiovascular disease (CVD) and progression to end-stage kidney disease (ESKD) in persons with type 1 diabetes.
MATERIALS AND METHODS
METHODS
We analysed plasma dp-ucMGP in stored baseline samples from a cohort of 667 persons with type 1 diabetes (baseline visit: 2009-2011). Information on mortality and CVD was obtained through linkage to registers. Cox-proportional hazards models were applied to estimate hazard ratios (HRs) of mortality, CVD and ESKD per one doubling of dp-ucMGP.
RESULTS
RESULTS
A total of 53 deaths were recorded during follow-up. Persons with higher dp-ucMGP (reflecting lower vitamin K status) had higher mortality in the unadjusted model (HR: 2.06 [95% confidence interval-CI: 1.22-3.45]), but not in the fully adjusted model (HR: 0.88 [95% CI: 0.44-1.73]). Particularly, adjustment for glomerular filtration rate and urinary albumin excretion rate attenuated the HR. A similar pattern was observed in unadjusted models for incidence of CVD (HR: 1.58 [95% CI: 1.03-2.42]) and risk of ESKD (HR: 7.62 [95% CI: 4.25-13.68]). In the fully adjusted models, the HRs became statistically insignificant.
CONCLUSION
CONCLUSIONS
In persons with type 1 diabetes, lower vitamin K status was associated with higher mortality, CVD and progression to ESKD, however, not after adjustment for other risk factors. Interventional studies are needed to elucidate the role of vitamin K in persons with type 1 diabetes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novo Nordisk Fonden
ID : NNF19OC0058130
Informations de copyright
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990‐2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982‐3021.
Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:323‐324.
Thompson G, Partridge J. Coronary calcification score: the coronary‐risk impact factor. Lancet. 2004;363:557‐559. doi:10.1016/S0140‐6736(04)15544‐X
Lindholt JS, Frandsen NE, Fredgart MH, et al. Effects of menaquinone‐7 supplementation in patients with aortic valve calcification: study protocol for a randomised controlled trial. BMJ Open. 2018;8:8. doi:10.1136/bmjopen‐2018‐022019
Fusaro M, Gallieni M, Porta C, Nickolas TL, Khairallah P. Vitamin K effects in human health: new insights beyond bone and cardiovascular health. J Nephrol. 2020;33:239‐249.
Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft‐tissue calcification. Adv Nutr. 2012;3:166‐173.
Cranenburg ECM, Koos R, Schurgers LJ, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010;104:811‐822. doi:10.1160/TH09‐11‐0786
Zwakenberg SR, Burgess S, Sluijs I, et al. Circulating phylloquinone, inactive matrix Gla protein and coronary heart disease risk: a two‐sample mendelian randomization study. Clin Nutr. 2020;39:1131‐1136. doi:10.1016/j.clnu.2019.04.024
Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78‐81. doi:10.1038/386078a0
Zhang S, Guo L, Bu C. Vitamin K status and cardiovascular events or mortality: a meta‐analysis. Eur J Prev Cardiol. 2019;26:549‐553. doi:10.1177/2047487318808066
Jespersen T, Møllehave LT, Thuesen BH, et al. Uncarboxylated matrix Gla‐protein: a biomarker of vitamin K status and cardiovascular risk. Clin Biochem. 2020;83:49‐56. doi:10.1016/j.clinbiochem.2020.05.005
Sarwar N, Gao P, Kondapally SS. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‐analysis of 102 prospective studies. Lancet. 2010;375:2215‐2222. doi:10.1016/S0140‐6736(10)60484‐9
Viñals C, Conget I, Granados M, Giménez M, Amor AJ. Evaluation of cardiovascular risk in people with type 1 diabetes: a comprehensive and specific proposed practical approach. Diabetes Ther. 2024;15:1831‐1844. doi:10.1007/s13300‐024‐01616‐4
Ho CY, Shanahan CM. Medial arterial calcification: an overlooked player in peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2016;36:1475‐1482.
Ho HJ, Komai M, Shirakawa H. Beneficial effects of vitamin k status on glycemic regulation and diabetes mellitus: a mini‐review. Nutrients. 2020;12:1‐16.
Dalmeijer GW, Van Der Schouw YT, Magdeleyns EJ, et al. Matrix gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2013;36:3766‐3771. doi:10.2337/dc13‐0065
Liabeuf S, Olivier B, Vemeer C, et al. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol. 2014;13:1‐8.
Sardana M, Vasim I, Varakantam S, et al. Inactive matrix gla‐protein and arterial stiffness in type 2 diabetes mellitus. Am J Hypertens. 2017;30:196‐201. doi:10.1093/ajh/hpw146
Bøgh Andersen I, Brasen CL, Nasimi H, et al. Serum vitamin K 1 associated to microangiopathy and/or macroangiopathy in individuals with and without diabetes. BMJ Open Diabetes Res Care. 2020;8:8. doi:10.1136/bmjdrc‐2019‐000961
Roumeliotis S, Roumeliotis A, Stamou A, et al. The association of dp‐ucmgp with cardiovascular morbidity and decreased renal function in diabetic chronic kidney disease. Int J Mol Sci. 2020;21:1‐13. doi:10.3390/ijms21176035
Theilade S, Lajer M, Persson F, Joergensen C, Rossing P. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care. 2013;36:715‐721. doi:10.2337/dc12‐0850
Theilade S, Lajer M, Hansen TW, et al. 24‐hour central aortic systolic pressure and 24‐hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross‐sectional study. Cardiovasc Diabetol. 2013;12:12. doi:10.1186/1475‐2840‐12‐122
Tougaard NH, Theilade S, Winther SA, et al. Carotid‐femoral pulse wave velocity as a risk marker for development of complications in type 1 diabetes mellitus. J Am Heart Assoc. 2020;9:9. doi:10.1161/JAHA.120.017165
Reinhard H, Hansen PR, Persson F, et al. Elevated NT‐proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant. 2011;26:3242‐3249. doi:10.1093/ndt/gfr009
Helweg‐Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39:26‐29. doi:10.1177/1403494811399958
Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39:30‐33. doi:10.1177/1403494811401482
Shea MK, Barger K, Booth SL, et al. Vitamin K status, cardiovascular disease, and all‐cause mortality: a participant‐level meta‐analysis of 3 US cohorts. Am J Clin Nutr. 2020;111:1170‐1177. doi:10.1093/ajcn/nqaa082
Griffin TP, Islam MN, Wall D, et al. Plasma dephosphorylated‐uncarboxylated matrix Gla‐protein (dp‐ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential. Sci Rep. 2019;9:9. doi:10.1038/s41598‐019‐54762‐2
Levy‐Schousboe K, Frimodt‐Møller M, Hansen D, et al. Vitamin K supplementation and arterial calcification in dialysis: results of the double‐blind, randomized, placebo‐controlled RenaKvit trial. Clin Kidney J. 2021;14:2114‐2123. doi:10.1093/ckj/sfab017
Saritas T, Reinartz S, Krüger T, et al. Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial. Clin Kidney J. 2022;15:2300‐2311. doi:10.1093/ckj/sfac184
Fauchier L, Boriani G, De Groot JR, et al. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace. 2021;23:1873‐1891.
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and D status in stages 3–5 chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:590‐597. doi:10.2215/CJN.06420909
Roumeliotis S, Liakopoulos V, Schurgers LJ. Vitamin K supplementation in chronic kidney disease patients: where is the evidence? Curr Vasc Pharmacol. 2022;20:121‐126. doi:10.2174/1570161120666220209145341
Narasaki Y, You AS, Malik S, et al. Dietary potassium intake, kidney function, and survival in a nationally representative cohort. Am J Clin Nutr. 2022;116:1123‐1134. doi:10.1093/ajcn/nqac215
Kyla Shea M, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv Nutr. 2012;3:158‐165.